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and the Dissociation With the
Prevailing Clinical Practice
The report (1) and editorial (2) in a recent issue of the Journal on
N-terminal pro–B-type natriuretic peptide (NT-proBNP) in the
management of patients with heart failure (HF) led to the
conclusion that B-type natriuretic peptide has not fulfilled original
expectations, although NT-proBNP provided advanced detection
of events and enhanced medication use. The editorial pointed out
that although NT-proBNP did not improve events, this could
partially reflect the need for a larger study, adoption of individu-
alized NT-proBNP targets, timing of the sampling for the nadir of
NT-proBNP, and threshold percentage rise in NT-proBNP for
up-titrating therapy. They also recommended consideration of the
patients’ age, other factors influencing BNP, systolic dysfunction,
and use of individual patient data in meta-analyses.
Trials of HF should include, along with the parameters under
study, a minimum of information currently used in the manage-
ment of patients. The cornerstone of the assessment of a patient
with HF is the history and physical examination (pulmonary rales,
elevated mean jugular venous pressure, and peripheral edema
[PERED]), although these conditions are insensitive and do not
correlate with hemodynamics (3). PERED is often undetected
until the patient has accumulated approximately 10 l of fluid (4).
Body weight (BW) is used in all clinical encounters with patients
with HF, and it should be a study variable in HF trials. Did the
researchers have BW measurements of their patients? If so, what
was the correlation between the BW and NT-proBNP percentage
perturbations? The quoted “negative” study (3) included a “posi-
tive” correlation (r  0.82) of proportional pulse pressure (systolic
blood pressure [SBP] diastolic blood pressure [DBP]/SBP) with
ardiac index. The mean SBP and DBP in Table 1 (1) were not
tatistically significant, although individual patient values are
eeded to calculate proportional pulse pressure.
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Reply
We would like to thank Dr. Madias for his valuable comments on
our study (1) assessing the effect of N-terminal pro–B-type
natriuretic peptide (NT-proBNP)-guided therapy in the manage-
ment of chronic heart failure (HF). As rightfully indicated,
quantification of fluid retention by physical examination is trou-
blesome, and the correlation between symptoms and severity of
cardiac dysfunction is poor. Trials such as the PRIMA (Can
PRo-brain-natriuretic peptide guided therapy of chronic heart
failure IMprove heart fAilure morbidity and mortality?) study (1)
ave been performed in order to assess the additive value of serial
NP or NT-proBNP measurements at the outpatient manage-
ent of HF patients.
Dr. Madias asks for data on body weight (BW). This was not
nitially reported as we felt that with outpatient visits occurring at
n interval of up to 3 months, the value of reporting outpatient
Ws with such wide intervals would be quite limited.
However, we did collect data on BW at index admission, at
ischarge, and at every outpatient visit during the follow-up period
f our study. During the index hospitalization because of acute
F, BW decreased with a median value of 4.48 kg (interquartile
ange: 1.8 to 6.2 kg). The change in BW during index admission
orrelated weakly, yet significantly, with changes in NT-proBNP
evels (r  0.144, p  0.016). At the outpatient clinic, there was
o statistically significant correlation between changes in BW and
T-proBNP levels.
In addition, Dr. Madias expresses an interest in possible
orrelations between the proportional pulse pressure (PPP) and
T-proBNP. We failed to find any correlation between PPP and
T-proBNP (correlation between PPP and NT-proBNP at ad-
ission: r 0.019, p 0.723; at discharge: r 0.035, p 0.532;
and at 2-week follow-up: r  0.023, p  0.689).
We also did not find a correlation in the subgroups of patients
ith left ventricular systolic dysfunction HF or those with pre-
erved left ventricular systolic function HF.
In conclusion, Dr. Madias rightfully points out the value of
hysical examination in the management of outpatient HF with
pecial emphasis on BW. In the PRIMA study, changes in BW
uring the index admission correlated weakly, yet statistically signif-
cantly, with NT-proBNP (1). No correlation was found between
utpatient NT-proBNP values and either BW or PPP, which for the
atter may be explained by the fact that PPP seems to reflect cardiac
utput, a parameter correlating poorly with BNP (2).
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